Treatment-related enrichment of particular NK cell subsets, or induction of NK cell activation has been associated with the therapeutic success of numerous MS drugs including interferon-beta, glatiramer acetate, and daclizumab [17], [18], [38]–[40]. Here, IFNB1 is linked to myeloid sarcoma.